| Outline of Final Research Achievements |
211At is one of the α-emitters expected to be applied to radionuclide therapy in a field of nuclear medicine, but its use is limited to manufacturing sites because of its short half-life. In this study, 211Rn was manufactured in collaboration with Argonne National Laboratory and Duke University in the United States, which has clinical experience with 211At, in order to create a 211Rn/211At generator to support studies using 211At in remote areas. Under the collaboration work, we tried to manufacture the 211Rn by using 6Li beam of the tandem accelerator ATLAS. And we also evaluated the effects of the radiolysis in organic solvents using high activity 211At. As a result, we confirmed the production of 211Rn at Argone National Laboratory. Moreover, when extracting highly radioactive 211At from nitric acid solution to organic solvent, no phenomenon due to radiolysis was observed.
|
